IRIS
DE LUCA, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.382
EU - Europa 2.185
AS - Asia 1.045
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 5.624
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.378
CN - Cina 498
UA - Ucraina 448
IE - Irlanda 435
GB - Regno Unito 333
TR - Turchia 329
SE - Svezia 276
IT - Italia 184
FR - Francia 171
DE - Germania 144
IN - India 91
FI - Finlandia 90
SG - Singapore 75
RU - Federazione Russa 73
VN - Vietnam 33
CZ - Repubblica Ceca 14
IR - Iran 10
EU - Europa 9
BE - Belgio 8
IL - Israele 5
GR - Grecia 4
CA - Canada 3
AM - Armenia 1
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
HK - Hong Kong 1
IM - Isola di Man 1
KR - Corea 1
MX - Messico 1
PH - Filippine 1
RO - Romania 1
Totale 5.624
Salva come PNG Salva come JPEG
Città #
Jacksonville 511
Chandler 508
Dublin 431
Southend 258
Izmir 192
Princeton 188
Nanjing 151
Wilmington 128
Ashburn 106
Beijing 94
Cambridge 84
Dearborn 84
Nanchang 58
Ann Arbor 51
Woodbridge 51
Singapore 49
Altamura 45
New York 42
Chieti 34
Dong Ket 33
Jiaxing 29
Houston 26
Boardman 25
Shenyang 25
Norwalk 24
Los Angeles 23
Grevenbroich 19
Kunming 19
Tianjin 19
Hebei 16
Washington 15
Brno 12
Changsha 12
Hangzhou 12
Leawood 12
San Mateo 12
Ardabil 10
Augusta 9
Cedar Knolls 9
Jinan 9
Torino 9
Helsinki 8
Brussels 7
Campobasso 7
Lanzhou 7
London 7
Monmouth Junction 7
Falls Church 6
Guangzhou 6
Munich 6
Ningbo 6
Pescara 6
Changchun 5
Hanover 5
Orange 5
Taizhou 5
Zhengzhou 5
San Vito Chietino 4
Borgomanero 3
Florence 3
Milan 3
Mumbai 3
Oxford 3
Pianella 3
Tappahannock 3
Teramo 3
Toronto 3
Walnut 3
Bangalore 2
Benevento 2
Cedar Lake 2
Düsseldorf 2
Frankfurt am Main 2
Fuzhou 2
Hefei 2
Isernia 2
L’Aquila 2
Naples 2
Olomouc 2
Phoenix 2
Rome 2
Seattle 2
Shanghai 2
Somerville 2
Stockholm 2
Andover 1
Antwerp 1
Archi 1
Auburn Hills 1
Basking Ridge 1
Berlin 1
Boston 1
Buffalo 1
Cairo 1
Candiolo 1
Central 1
Chengdu 1
Domusnovas 1
Douglas 1
Dragoni 1
Totale 3.625
Salva come PNG Salva come JPEG
Nome #
IL 13 in multiple sclerosis 116
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 106
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 90
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 89
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 84
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 83
Increasing age at disability milestones among MS patients in the MSBase Registry 82
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 82
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 80
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 80
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 79
Effect of TNF intraneural injection into the rat sciatic nerve 78
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 78
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 78
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 78
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 77
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 76
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 76
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 75
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 74
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 74
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 73
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 73
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 73
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 72
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 72
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 70
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 70
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 70
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 69
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 69
Nail loss after teriflunomide treatment: a new potential adverse event 69
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 68
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 68
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 68
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 68
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 68
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 67
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 66
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 66
Interferon beta1b: the Chieti experience 65
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 65
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 65
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 65
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 65
Effect of rhTNF-alpha injection into rat sciatic nerve 64
JCV-Ab serostatus in MS patients treated with Natalizumab 64
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 63
Effect of rhTNF-a injection into rat sciatic nerve 63
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 63
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 61
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 61
Mononeuropathy following subcutaneous interferon-β injection 61
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 61
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 61
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 61
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 61
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 59
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 59
Interferon β 1b: The Chieti experience 59
Interferone beta1b: bilancio su un gruppo di 30 pazienti 58
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 58
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 57
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 56
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 56
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 55
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 55
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 55
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 54
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 54
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 51
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 50
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 50
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 49
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 49
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 47
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 45
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 43
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 43
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 43
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 42
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 36
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 35
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 34
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 33
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 33
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 32
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 31
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 30
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 30
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 27
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 18
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 17
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 12
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose 11
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 5
Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge 5
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 2
Totale 5.761
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.871
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.871
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020747 0 82 7 34 66 92 117 105 16 90 134 4
2020/2021616 86 0 91 1 37 123 1 2 80 68 58 69
2021/2022357 2 4 6 57 11 11 16 34 32 7 54 123
2022/20231.321 104 152 72 158 143 272 81 93 171 17 29 29
2023/2024653 46 30 38 16 37 225 145 30 0 31 5 50
2024/2025127 117 10 0 0 0 0 0 0 0 0 0 0
Totale 5.761